D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Immunology D-index 72 Citations 24,203 222 World Ranking 959 National Ranking 522
Medicine D-index 80 Citations 26,611 285 World Ranking 9617 National Ranking 5191

Research.com Recognitions

Awards & Achievements

Member of the Association of American Physicians

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Immune system
  • Gene

His primary areas of investigation include Immunology, Immune system, Immunity, Cancer and Antigen. His Immunology research incorporates themes from Cytotoxic T cell and Breast cancer. His biological study deals with issues like Cancer research, which deal with fields such as Merkel cell polyomavirus.

His study looks at the relationship between Immune system and fields such as Adjuvant, as well as how they intersect with chemical problems. His Immunity study combines topics from a wide range of disciplines, such as Vaccination, Tetanus, Virology, T cell and Humoral immunity. His work investigates the relationship between IL-2 receptor and topics such as Pathogenesis that intersect with problems in FOXP3.

His most cited work include:

  • Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. (3925 citations)
  • Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. (479 citations)
  • Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. (458 citations)

What are the main themes of his work throughout his whole career to date?

Mary L. Disis mostly deals with Immunology, Immune system, Cancer, Antigen and Breast cancer. His study involves Immunity, T cell, Antibody, Vaccination and Immunotherapy, a branch of Immunology. His research is interdisciplinary, bridging the disciplines of Adjuvant and Immune system.

His Cancer research is multidisciplinary, incorporating elements of Cancer research, Disease, Immunization and Bioinformatics. His research investigates the connection with Antigen and areas like Cytotoxic T cell which intersect with concerns in CD8. His Breast cancer research includes themes of Autoantibody, Genetically modified mouse and Oncology.

He most often published in these fields:

  • Immunology (52.62%)
  • Immune system (37.81%)
  • Cancer (31.89%)

What were the highlights of his more recent work (between 2016-2021)?

  • Cancer (31.89%)
  • Internal medicine (19.82%)
  • Breast cancer (23.23%)

In recent papers he was focusing on the following fields of study:

His primary scientific interests are in Cancer, Internal medicine, Breast cancer, Immune system and Cancer research. The various areas that Mary L. Disis examines in his Cancer study include Acquired immune system, Carcinoma and MEDLINE. Within one scientific family, Mary L. Disis focuses on topics pertaining to Oncology under Internal medicine, and may sometimes address concerns connected to Tumor-infiltrating lymphocytes, Chemotherapy and Metastatic breast cancer.

When carried out as part of a general Breast cancer research project, his work on Mammary tumor is frequently linked to work in In patient, therefore connecting diverse disciplines of study. His study on Immune system is covered under Immunology. His work deals with themes such as Adjuvant, Stem cell, Triple-negative breast cancer, Cytotoxic T cell and Genetically modified mouse, which intersect with Cancer research.

Between 2016 and 2021, his most popular works were:

  • Gene expression markers of Tumor Infiltrating Leukocytes (209 citations)
  • Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. (105 citations)
  • Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. (100 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Gene
  • Immune system

His scientific interests lie mostly in Cancer, Immune system, Immunotherapy, Internal medicine and Immunology. His biological study spans a wide range of topics, including Acquired immune system and Public relations. Mary L. Disis interconnects Cognitive science and Biomarker in the investigation of issues within Immune system.

Mary L. Disis focuses mostly in the field of Immunotherapy, narrowing it down to topics relating to Tumor microenvironment and, in certain cases, Tumor-infiltrating lymphocytes, Antigen processing, Immunity and Cancer immunotherapy. The Internal medicine study combines topics in areas such as Gastroenterology and Oncology. In general Immunology, his work in Antigen and ELISPOT is often linked to Outcome linking many areas of study.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Tyler J Curiel;George Coukos;Linhua Zou;Xavier Alvarez.
Nature Medicine (2004)

5369 Citations

Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.

K. L. Knutson;M. L. Disis.
Cancer Immunology, Immunotherapy (2005)

744 Citations

Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.

Mary L. Disis;Emanuel Calenoff;Graham McLaughlin;Ann E. Murphy.
Cancer Research (1994)

706 Citations

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients

Keith L. Knutson;Kathy Schiffman;Mary L. Disis.
Journal of Clinical Investigation (2001)

612 Citations

Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines

Mary L. Disis;Theodore A. Gooley;Kristine Rinn;Donna Davis.
Journal of Clinical Oncology (2002)

538 Citations

Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.

Mary L. Disis;Kenneth H. Grabstein;Paul R. Sleath;Martin A. Cheever.
Clinical Cancer Research (1999)

528 Citations

Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines

Mary L. Disis;Helga Bernhard;Faith M. Shiota;Susan L. Hand.
Blood (1996)

519 Citations

High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.

Mary L. Disis;Serenella M. Pupa;Julie R. Gralow;Ruggero Dittadi.
Journal of Clinical Oncology (1997)

482 Citations

Immune Regulation of Cancer

Mary L. Disis.
Journal of Clinical Oncology (2010)

436 Citations

Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

Ulrich Keilholz;Jeffrey Weber;James H. Finke;Dmitry I. Gabrilovich.
Journal of Immunotherapy (2002)

379 Citations

Editorial Boards

JAMA oncology
(Impact Factor: 33.006)

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Mary L. Disis

Jeffrey Schlom

Jeffrey Schlom

National Institutes of Health

Publications: 60

James L. Gulley

James L. Gulley

National Institutes of Health

Publications: 52

Francesco M. Marincola

Francesco M. Marincola

National Institutes of Health

Publications: 51

Jérôme Galon

Jérôme Galon

Université Paris Cité

Publications: 46

George Coukos

George Coukos

University of Lausanne

Publications: 41

Keith L. Knutson

Keith L. Knutson

Mayo Clinic

Publications: 38

Elizabeth M. Jaffee

Elizabeth M. Jaffee

Johns Hopkins University

Publications: 37

Bernard A. Fox

Bernard A. Fox

Earle A. Chiles Research Institute

Publications: 35

Michael A. Morse

Michael A. Morse

Duke University

Publications: 35

Lloyd J. Old

Lloyd J. Old

Ludwig Cancer Research

Publications: 32

Laurence Zitvogel

Laurence Zitvogel

Institut Gustave Roussy

Publications: 32

Yvonne Paterson

Yvonne Paterson

University of Pennsylvania

Publications: 31

Timothy M. Clay

Timothy M. Clay

Duke University

Publications: 31

Akseli Hemminki

Akseli Hemminki

University of Helsinki

Publications: 30

Antonin de Fougerolles

Antonin de Fougerolles

Alnylam Pharmaceuticals (United States)

Publications: 29

Kyogo Itoh

Kyogo Itoh

Kurume University

Publications: 28

Trending Scientists

Jonathan Berant

Jonathan Berant

Tel Aviv University

Saras D. Sarasvathy

Saras D. Sarasvathy

University of Virginia

Herman P. Schwan

Herman P. Schwan

University of Pennsylvania

Mamoru Sugita

Mamoru Sugita

Nagoya University

Peter H. Raven

Peter H. Raven

Missouri Botanical Garden

Charles A. Simenstad

Charles A. Simenstad

University of Washington

Panagiotis N. Skandamis

Panagiotis N. Skandamis

Agricultural University of Athens

Manuela E. Gomes

Manuela E. Gomes

University of Minho

Vadivel Ganapathy

Vadivel Ganapathy

Texas Tech University Health Sciences Center

Robert S. Dietz

Robert S. Dietz

Arizona State University

Louis Marie Prieur

Louis Marie Prieur

Centre national de la recherche scientifique, CNRS

Greg M. Rose

Greg M. Rose

United States Department of Veterans Affairs

Christopher Power

Christopher Power

University of Alberta

Christopher F. Chabris

Christopher F. Chabris

Geisinger Health System

Edouard Louis

Edouard Louis

University of Liège

Adriano Piattelli

Adriano Piattelli

University of Chieti-Pescara

Something went wrong. Please try again later.